BroadOak Capital Partners, a life sciences-focused investment and advisory firm, has secured more than $200 million in permanent capital, expanding its capacity to invest flexibly across the life sciences ecosystem. The new capital strengthens BroadOak’s ability to support companies in life sciences tools, diagnostics, and biopharma services while eliminating the traditional constraints of fund timelines.
The investment comes from BroadOak’s principals and strategic partner Research Corporation Technologies (RCT), a firm known for its deep roots in advancing biomedical innovation. This structure provides BroadOak with long-duration, evergreen capital that can be deployed opportunistically across market cycles. This approach offers portfolio companies greater continuity and adaptability as they grow and evolve.
The additional capital underscores BroadOak’s continued momentum following a year of record investor distributions and the successful closings of its BroadOak Income Fund and Fund VI. These vehicles have allowed the firm to expand its reach into both equity and credit investments within the life sciences sector, leveraging a strategy that blends private equity, structured finance, and strategic advisory expertise.
Founded in 2005, BroadOak has been an active partner to more than 70 companies across life sciences tools, diagnostics, and related service providers. The firm’s investments often target companies that enable scientific research, biomanufacturing, and therapeutic development, critical components of the broader biomedical innovation ecosystem. By combining operational guidance with flexible financial structures, BroadOak positions itself as a value-added partner to growth-stage businesses seeking strategic capital and expertise.
With this new permanent capital, BroadOak aims to deepen its support for companies at the intersection of science and infrastructure, particularly those advancing new platforms in genomics, precision medicine, and bioprocessing. The firm plans to continue deploying a mix of equity and debt capital to high-potential ventures that play a central role in improving research efficiency, clinical outcomes, and global health innovation.
KEY QUOTES:
“This is a transformational milestone for BroadOak. We can now lean into what we believe is an excellent environment for life sciences investors while assuring stakeholders of our longevity.”
Bill Snider, Partner, BroadOak Capital Partners
“The commitment of permanent capital assures that BroadOak has even greater flexibility to achieve successful results for all its managed funds and programs across stakeholders.”
Shaun Kirkpatrick, President, Research Corporation Technologies (RCT)
